Tag:
pay for delay deals
Latest Headlines
Latest Headlines
U.K. goes after GSK for decade-old pay-for-delay deal
Pay-for-delay deals are disliked by regulators on both sides of the Atlantic. A month after the U.S. Supreme Court heard arguments on the practices, regulators in the U.K. have turned to a decade-old deal, no longer place, to accuse GlaxoSmithKline of paying competitors to keep generics off the market.
Supreme Court could upend pay-for-delay deals
Now that Obamacare has had its day at the Supreme Court, pharma has another case to worry about. The longstanding debate over "pay-for-delay" deals with generics companies could soon make its way to the high court, legal experts say. And if it does, branded drugmakers and generics companies would face a wholesale shift in their business strategies.
Appeals court ruling threatens pay-to-delay deals
A federal appeals court pulled a pay-to-delay challenge out of mothballs, forcing Merck to fight claims that its Schering-Plough unit delayed generic versions of its potassium drug K-Dur. But Merck isn't the only drugmaker that should keep an eye on this case.
Senate bill would nix 180-day generics exclusivity
Here's one way to curb pay-for-delay patent settlements: Broaden the field of successful patent challengers. A bill set for introduction in the U.S. Senate would amend the Hatch-Waxman Act, which
Less cash, more promises in pay-to-delay deals
The debate over pay-to-delay deals played out in microcosm at an American Bar Association panel yesterday. As Legal Times reports, the Federal Trade Commission's deputy assistant director Bradley
CBO: Pay-to-delay ban could save $4.8B
The Congressional Budget Office has analyzed the proposed pay-to-delay ban, and its money-saving estimate comes in at almost $5 billion. According to CBO, the Preserve Access to Affordable Generic
FTC: Pay-for-delay ban would save $2.67B
It's no coincidence that the Federal Trade Commission released new "pay for delay" numbers yesterday, just as the Congressional budget-cutting committee nears its deadline. The FTC wanted to
Obama plan hits pharma with rebates, pay-to-delay ban
President Obama's deficit-cutting plan hits pharma with a one-two-three punch. As he's advocated before, Obama would impose higher drug rebates on dual-eligibles, the low-income Medicare patients who
FTC mulls agency action against pay-for-delay
The Federal Trade Commission is considering using its rule-making power to stop so-called pay-for-delay deals between branded drugmakers and generics companies after failing to get judges or Congress
